For the 5% to 20% of patients with generalized myasthenia gravis who have suboptimal response to pyridostigmine or substantial adverse effects, it may be time to consider immunosuppressive therapy. This short review offers guidance on choice of agents.
Real World Experience with Tixagevimab/Cilgavimab in B-Cell-Depleted Patients
Early results were positive in a study of the preventive treatment of COVID-19 with xagevimab/cilgavimab for patients who were unlikely to respond sufficiently or at all to vaccination.
Case Study: EBV-Associated Primary CNS Lymphoma in a Patient on Long-Term Mycophenolate Mofetil
Questions about safe protocols arise from a case in which a patient spent five years on a daily immunosuppressant regimen to control scleroderma-related skin tightness.
Improving Therapies for Children With Severe Aplastic Anemia
Severe aplastic anemia in children is fatal if not treated appropriately. Recent developments in treatment regimen suggest a new standard of care is afoot.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy